-
Board Certification
American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5( out of 58 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
October 30, 2025HUNTSMAN CANCER CENTERDr. Baron is highly gifted with expertise, warmth and kindness. She is patient and takes all the time needed to answer questions or explain things to us. She is truly superlative.
October 27, 2025HUNTSMAN CANCER CENTERShe was a great doctor
October 13, 2025HUNTSMAN CANCER CENTERDr. Baron is very concerned about the patients health and also about you as a person.
October 13, 2025HUNTSMAN CANCER CENTERShe was kind, caring and explained everything.
October 05, 2025HUNTSMAN CANCER CENTERDr. Baron is extremely thorough and kind. She listens to every question that I have and her answers are easy to understand. She is an outstanding physician !
October 05, 2025HUNTSMAN CANCER CENTERWe love Dr Baron and her staff. She is a through, caring and experienced provider who cares for her patients and explains things with consideration for the patient.
October 05, 2025HUNTSMAN CANCER CENTERI saw the PA who was outstanding.
September 01, 2025HUNTSMAN CANCER CENTERverry good
August 17, 2025HUNTSMAN CANCER CENTERVery caring and interested in you personally
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Assistant Professor (Clinical)
Academic Divisions Hematology & Hematologic Malignancies
Board Certification American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology & Oncology - Huntsman Cancer Institute/University of Utah Spencer Fox Eccles School of Medicine Chief Fellow Fellowship Hematology & Oncology - Huntsman Cancer Institute/University of Utah Spencer Fox Eccles School of Medicine Fellow Residency Internal Medicine - University of Utah School of Medicine Resident Professional Medical Medicine - University of Toledo College of Medicine and Life Sciences M.D. Undergraduate Advanced Spanish Study Abroad Program - La Universidad de Gran Rosario Undergraduate Spanish - Ohio State University, Honors College B.A. Undergraduate Biology - Ohio State University, Honors College B.S. Selected Publications
Journal Article
- Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT (2025). Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. (Read full publication)
- Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients with Follicular Lymphoma treated with BR vs RCHOP-like regimens . Clin Lymphoma Myeloma Leuk, (0).
- Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clin Lymphoma Myeloma Leuk. (Read full publication)
- Gociman S, Baron K, Hu B, Zussman J, Madigan LM (2022). Blistering Lesions Associated With Loncastuximab Tesirine. JAMA Dermatol, 158(7), 831-832. (Read full publication)
- Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. (Read full publication)
- Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559. (Read full publication)
- Carlson SJ, Fleig A, Baron MK, Berg IA, Alber BE (2019). Barriers to 3-Hydroxypropionate-Dependent Growth of Rhodobacter sphaeroides by Distinct Disruptions of the Ethylmalonyl Coenzyme A Pathway. J Bacteriol, 201(4). (Read full publication)
Letter
- Baron MK, Osborn JD, Tao R, Lee CJ (2019). Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome. [Letter to the editor]. Leuk Lymphoma, 61(1), 231-233. (Read full publication)
(
out of
58
reviews
)